ADVENTRX Pharmaceuticals is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications arising from sickle cell disease and has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in various serious and life-threatening diseases and conditions. For more information, visit the company’s Web site at www.adventrx.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: